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ABSTRACT
Endovascular mechanical thrombectomy (EVT) is widely 
accepted as the first- line treatment for acute ischemic 
stroke in patients with large vessel occlusion. Being 
an invasive treatment, this method is associated with 
various preoperative, perioperative, and postoperative 
complications. These complications may influence peri- 
interventional morbidity and mortality and therefore 
treatment efficacy and clinical outcome. The aim of 
this review is to discuss the most common types 
of complications associated with EVT, the probable 
mechanisms of injury, and effective methods to manage 
and prevent complications.
INTRODUCTION
The introduction of endovascular mechanical 
thrombectomy (EVT) using stent retriever devices 
has led to improvements in technical success, reca-
nalization rates, and outcomes in selected patients 
with ischemic stroke caused by large vessel occlu-
sion (LVO). There is also limited but promising 
evidence for safety and efficacy using EVT for 
middle- vessel occlusions or for isolated occlu-
sion of the posterior cerebral artery.1 Neverthe-
less, despite the technical advancement and high 
success rates, device- or procedure- related compli-
cations reported from randomized controlled trials 
(RCTs) are between 4% and 29%.2–7 The indica-
tions for EVT are continuously being expanded—
for example, to prolonged time windows. Several 
RCTs are currently seeking to examine further open 
questions regarding patient selection and efficacy 
of EVT—for example, in cases of LVO with low 
National Institutes of Health Stroke Scale (NIHSS) 
score or large infarct volumes. The increasing 
number of patients eligible for EVT might also lead 
to an increase in the incidence of complications 
or a shift towards certain complications. There-
fore, awareness of potential complications of EVT, 
immediate recognition, appropriate management, 
and implementation of prevention strategies are 
crucial.
We can divide the types of complications into two 
groups: extracranial and intracranial. Extracranial 
complications mainly arise from access difficulties 
and can lead to iatrogenic dissection or vasospasm 
of the access vessel. Intracranial complications can 
be further subdivided into hemorrhagic and isch-
emic complications. These include symptomatic 
intracranial hemorrhage (sICH) and subarachnoid 
hemorrhage (SAH) or embolization within the same 
or a new vascular territory. Furthermore, mechan-
ical strain on intracranial vessels caused by EVT 
may lead to long- term complications and sequelae, 
such as intracranial stenosis or chronic dissec-
tion. The aim of this review is to discuss the most 
common types of complications associated with 
EVT, the probable mechanisms of injury, and effec-
tive methods to manage and prevent complications.
Extracranial or access site complications
Topic
Gaining straightforward access and overcoming access 
difficulties are important to minimize procedure time. 
Prolonged procedure times delay clot retrieval, can 
lead to increased complication rates, and eventually, 
result in worse clinical outcome. Groin hematoma 
is the most frequent access site complication and a 
range of 2–10% is reported in RCTs.3 4 6 8 Next to 
groin hematoma, groin infection, nerve and vessels 
injury have been described, but are rare and need to 
be handled in each kind of endovascular treatment. 
The value of radial access for patients with challenging 
vascular anatomy is more and more discussed but so 
fas has not been established as a standard procedure in 
treatment of LVOs 9 .
MANAGEMENT
The management of a groin hematoma varies 
from watchful observation to emergency vascular 
surgery. Treatment options such as implantation of 
covered stents or the minimal invasive option of 
percutaneous thrombin injection to treat growing 
pseudoaneurysms should be available.
PREVENTION
Gaining vascular access under ultrasound guidance 
minimizes the number of puncture attempts and 
reduces access site complications such as groin or 
retroperitoneal hematoma, formation of pseudoan-




Vasospasm can be induced through mechanical 
irritation of the vessel wall during catheter or 
guidewire manipulation. The rate of vasospasm 
reported in RCTs is 3.9–23%.5 6 8 Vasospasm can 
decrease cerebral blood flow and sometimes leads 
to misidentification of a residual thrombus or intra-
cranial stenosis. Residual thrombus and vessel wall 
irregularities after thrombectomy are predictors of 
early reocclusion and associated with an unfavor-
able outcome.11 However, clinical deterioration 
directly linked to extracranial vasospasm has not 
yet been reported.
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MANAGEMENT
Selective injection of a calcium blocker such as nimodipine 
(0.5–1 mg/500 mL infusion), either as a bolus or continuously 
through the flushing line of the guiding catheter, can be considered. 
It is important to avoid at the same time systemic hypotension which 
might occur while the infusion is being administered, particularly 
in a patient with acute LVO. Therefore, it is essential to monitor 
for a drop in blood pressure and to take counteractive measures, if 
necessary.
PREVENTION
Administration of nimodipine as a prophylactic measure against 
vasospasm in EVT is not recommended owing to the potential 
risks of hypotension and induction of a cerebral steal phenom-
enon in patients with LVO.
Dissection
Topic
Iatrogenic arterial dissections can occur at the puncture site or during 
any catheter or guidewire manipulation.12 Dissections during EVT of 
acute ischemic stroke are more prevalent in the cervical vessel (83%) 
than at the puncture site or in intracranial vessels (17%)12 (figure 1). 
Besides vessel tortuosity, smoking seems to be a risk factor for iatro-
genic dissections.12 The rates of dissection during EVT reported in 
RCTs range between 0.6% and 3.9%.2 3 6
MANAGEMENT
To manage dissection, it is essential to diagnose it as early as possible. 
A dissection with penetration of the adventitia can be seen as contrast 
extravasation, whereas an intimal flap can be seen as double lumen 
or a contrast pocket on digital subtraction angiography (DSA) 
images. Indirect signs indicating a dissection are newly appearing 
stenosis with the so- called string sign on angiography, or an evolving 
pseudoaneurysm. Bearing in mind the benign course of iatrogenic 
dissections, especially in the case of a small flap, watchful obser-
vation seems justified.12 In the case of progression or increasing 
stenosis leading to hemodynamic impairment or thromboembolic 
complications, treatment of the dissection by stent placement may be 
necessary. However, the consequent need to administer antiplatelet 
therapy can increase the risk of sICH.
PREVENTION
The risk for iatrogenic dissection is increased in tortuous anatomy. 
Evaluation of the access vessel anatomy on non- invasive imaging 
in patients undergoing EVT is important to plan the interven-
tional approach (ie, use of distal access catheter).
Intracranial complications
Procedure- related complications of EVT using stent retriever 
devices can be classified as follows:
1. Hemorrhagic complications due to vessel perforation caus-
ing subarachnoid or intracerebral hemorrhage and hemor-
rhagic transformation.
2. Embolic complications with thrombus embolization (1) in 
previously unaffected (ie, not initially hypoperfused) territo-
ries, or (2) in the distal vascular bed of the initially occluded 
territory.




Hemorrhagic complications are feared complications of acute 
ischemic stroke treatment. According to the classification of 
Figure 1 (A) Digital subtraction angiography (DSA) of the right 
common carotid artery at the beginning of the procedure. (B) DSA run of 
the right internal carotid artery (ICA) with an arrow pointing to the tip 
of the balloon- guide catheter and narrowing of the vessel wall. (C) After 
endovascular thrombectomy a hemodynamically relevant and increasing 
stenosis due to a dissection can be observed in the cervical portion of 
the right ICA. (D) DSA run of the right ICA after stent placement in the 
dissected part of the vessel wall.
Table 1 Classification of hemorrhagic events after ischemic stroke and reperfusion therapy consensus (Heidelberg Bleeding Classification)13 
compared with ECASS III14
Anatomic intracranial 
hemorrhage classification ECASS type Description
1   Hemorrhagic transformation of infarcted brain tissue
1a HI1 Scattered small petechiae, no mass effect
1b HI2 Confluent petechiae, no mass effect
1c PH1 Hematoma within infarcted tissue, occupying <30%, no substantive mass effect
2   Intracerebral hemorrhage within and beyond infarcted brain tissue
PH2 Hematoma occupying 30% or more of the infarcted tissue, with obvious mass effect
3   Intracerebral hemorrhage outside the infarcted brain tissue or intracranial- extracerebral hemorrhage
3a   Parenchymal hematoma remote from infarcted brain tissue
3b   Intraventricular hemorrhage
3c   Subarachnoid hemorrhage
3d   Subdural hemorrhage
HI, hemorrhagic infarction; PH, parenchymatous hematoma.
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bleeding events after ischemic stroke and reperfusion therapy 
consensus (Heidelberg Bleeding Classification),13 the following 
subtypes can be differentiated anatomically: hemorrhagic trans-
formations, intracerebral hemorrhage, remote parenchymal 
hematoma, intraventricular hemorrhage, subarachnoid hemor-
rhage, and subdural hemorrhage (table 1). According to the 
consensus, hemorrhage is classified as symptomatic if worsening 
of the NIHSS score ≥4 points occurs or worsening by ≥2 points 
occurs in one NIHSS category and if alternative explanations 
for this deterioration are lacking. However, several different 
classifications for hemorrhagic complications have been used in 
the past, thus reporting is not uniform and comparison between 
trials may be difficult.
Reasons for hemorrhagic complications can vary depending 
on whether they occur before, during, or after the thrombec-
tomy procedure, and on the patient’s comorbidities and blood 
pressure.
Vessel perforation
One of the most feared and serious complications is arterial 
perforation with a microwire, microcatheter or stent retriever 
(SR), because it may result in poor functional outcome in up 
to 75% of cases and high mortality, exceeding 50%.14 Arterial 
perforation is usually identified by extravasation of contrast 
agent in a DSA run (figure 2) and can cause a cushing reflex. 
Vessel perforation has been reported in 0.6% to 4.9% of patients 
undergoing EVT in large randomized series of patients with 
anterior circulation stroke.2–6 A large retrospective review found 
a prevalence of 1.0%.14 15 Most perforations occur either when 
there are difficulties crossing the occlusion site or during deploy-
ment or retrieval of the SR. EVT in calcified thrombi has also 
been reported to be linked to a higher rate of vessel perfora-
tion.16 The current trend of expanding the indications for EVT to 
medium and distal vessel occlusions might result in an increased 
incidence of vessel perforation or hemorrhagic complications.17
MANAGEMENT
Arterial perforation requires rapid action, but the perforating device 
should not be pulled back immediately as it might be sealing the 
perforation site. To control active bleeding, detachable coils can be 
used at the perforation site. A promising strategy is to deploy the 
coil without detaching it, since the flow arrest achieved by the coil 
deployment is often enough to reach hemostasis and to seal the site of 
injury without the need to sacrifice the affected vessel segment. The 
size of the coil should more or less match the diameter of the perfo-
rated vessel. Alternatively, inflation of a balloon for several minutes 
can be performed in the affected vessel proximal to the hemorrhage 
site; however, the device preparation takes longer than for the use 
of coils.14 18 If bleeding persists after a period of coil placements or 
balloon inflations (each attempt up to 5–10 min), permanent occlu-
sion of the affected vessel segment by detaching the coils or injection 
of a liquid embolic agent (eg, n- butyl cyanoacrylate as glue, Onyx, 
or precipitating hydrophobic injectable liquid) is necessary (figure 2). 
The number of attempts that are made before permanent occlusion 
of the affected vessel is necessary should be determined according to 
the clinical setting and situation. Nevertheless, a further supportive 
measure if bleeding occurs is the temporary reduction of blood pres-
sure. A flat panel cone beam CT scan is a valuable tool for immediate 
depiction of the extension and location of the hemorrhage to enable 
a decision to be made on whether immediate neurosurgical inter-
vention—for example, insertion of a ventricular drain or hematoma 
evacuation, is needed.
PREVENTION
Using a J- shaped microwire tip for navigation across and distal to 
the occlusion site reduces the risk of perforation by inadvertently 
catheterizing small vessel branches. Using a microcatheter alone 
without a microwire crossing a lesion can be an option, but does 
not prevent perforation, which is also possible with a micro-
catheter on its own. The use of first- line aspiration techniques 
compared with first- line stent retriever, for example, did not 
show fewer arterial perforations in the ASTER Trial.19 Further-
more, deployment of a SR by unsheathing rather than pushing 
it out of the microcatheter ensures that the SR is deployed in 
a catheterizable vessel. Uncontrolled forward pushing of the 
SR out of the microcatheter during deployment carries the risk 
of perforation, especially at a bifurcation site. If the vascular 
anatomy is unclear, a selective microcatheter injection helps to 
define the optimal device deployment zone. For EVT of medium 
or distal vessel occlusion, the use of dedicated SR devices 
adapted to the smaller vessel diameter or of a semi- deployed 
SR can help to reduce the mechanical strain on the arterial wall 
and on small perforating arteries arising from the vessel segment 
during device deployment and retrieval.
Subarachnoid hemorrhage (SAH)
SAH after EVT is not exclusively observed after vessel perfo-
ration or dissection, but may occur, even if no contrast extrav-
asation is visible during the intervention, as angiographically 
occult SAH. This type of treatment- related SAH is believed to 
be caused by stretching or avulsion of small perforating arteries 
in the subarachnoid space, typically in the Sylvian fissure or 
at the level of the insula, by mechanical traction of the device 
during the retrieval maneuver. Emerging evidence suggests 
Figure 2 DSA run of the left middle cerebral artery after endovascular 
thrombectomy maneuver showing an extravasation in the (A) arterial 
and (B) parenchymal phase with origin at the previous position of the 
stent rettriever. (C) Owing to the persistent bleeding, embolization of 
the affected vessel segment by injection of n- butyl cyanoacrylate was 
performed.
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that angiographically occult SAH is not related to neurolog-
ical outcome.15 Some retrospective studies suggested fewer 
SAHs after the use of aspiration techniques than after use of SR 
techniques.20 However, recent RCTs have not confirmed these 
results.19
Hemorrhagic transformations and symptomatic intracranial 
hemorrhage
Hemorrhagic transformation usually occurs in infarcted brain 
parenchyma.21 However, remote parenchymal hematomas of 
non- ischemic brain tissue have also been observed.22 The Heidel-
berg Bleeding Classification distinguishes between hemorrhagic 
infarction HI1, HI2, parenchymatous hematoma PH1 and PH2, 
of which only the latter has been shown to cause clinical deteri-
oration and is associated with worse outcome.23 24
Embolic and ischemic complications
Topic
The modified thrombolysis in cerebral infarction (mTICI) 
grading system is a tool for determining the response of EVT and 
thrombolytic therapies, with grade 3 meaning complete perfu-
sion and grade 0 meaning no perfusion.25 Embolic complications 
influence this score, although patients with complete (mTICI 
3) and near- complete (mTICI 2c) reperfusions seem to have 
comparable outcomes.26 Two types of embolic complications 
can occur during mechanical thrombectomy maneuvers: (1) 
emboli in previously unaffected (ie, not initially hypoperfused) 
territories, or (2) emboli in the distal vascular bed of the initially 
occluded territory, leading to incomplete (<mTICI 3), rather 
than complete (mTICI 3) reperfusion. Both types of emboliza-
tion are thought to arise from fragmentation of the clot during 
retrieval, while only a minority of distal emboli are already 
present before the intervention.27 Several prevalent factors 
influencing the likelihood of embolic complications have been 
suggested. These include physical and histological clot proper-
ties,28 29 use of protection and flow- arrest devices (balloon- guide 
catheters and/or distal aspiration),30–34 and pretreatment with 
intravenous tissue plasminogen activator,35 and are potentially 
increased when using contact aspiration rather than a SR.36 Both 
embolization in new territories and distal embolization have 
generally been associated with worse outcome,35 37 because they 
may cause new ischemic lesions,35 38 and also aggravate ischemia 
by impairing the collateral circulation to the primarily affected 
territory.27 However, not all emboli cause infarcts and thus not 
all are clinically apparent.31 According to a recent systematic 
literature review, the combined incidence of distal arterial embo-
lization and infarcts in new vascular territories during EVT for 
anterior circulation stroke has been reported to be 4–6%.39
Distal embolization
Because around 90% of intracranial thrombi in LVO are found 
to be unilocular,27 in theory, a rate of TICI 2a and TICI 2b 
reperfusion exceeding 10% must be regarded as caused, at least 
partially, by iatrogenic distal embolization.40 41 However, there 
is no consensus on how to classify distal embolization, and most 
studies have reported its incidence as a separate variable from 
the TICI score. The incidence of distal embolization during 
interventions for posterior circulation stroke has been reported 
to be as high as 30%, which is higher than for anterior circu-
lation strokes.41 Different rates of distal embolization between 
anterior and posterior circulation strokes probably arise from 
the lack of flow arrest during posterior circulation stroke inter-
ventions.41 New thrombectomy devices designed to further 
increase complete reperfusion rates and to reduce the rates of 
peri- interventional distal embolization are currently being eval-
uated. Options include incorporation of a distal protection zone 
in the SR design or larger- bore aspiration catheters.
Emboli and infarcts in a new vascular territory
Emboli in new vascular territory are usually graded based on 
the latest angiographic control runs, while the classification of 
an infarct in new territory requires postinterventional imaging.42 
To classify emboli or infarcts as occurring in a ‘new territory’, 
the vascular territory at risk has to be identified and preinter-
ventional imaging has to be carefully evaluated for the pres-
ence of concomitant vessel occlusion prior to the interventional 
procedure.42
MANAGEMENT
The clinical benefit from the management of distal emboli 
should always outweigh the risks of clinical deterioration. If the 
Figure 3 Flow chart of a practical algorithm showing how to deal 
with residual occlusions or distal emboli to a new or target vascular 
territory in endovascular mechanical thrombectomy. ACA, anterior 
cerebral artery; IAT, intra- arterial; thrombolysis; mTE, mechanical 
thrombectomy; PCA, posterior cerebral artery; SR, stent retriever.
Figure 4 (A) DSA run of the right middle cerebral artery (MCA) after 
endovascular thrombectomy with repeated stent retriever retrievals, 
initially interpreted as residual vasospasm. (B) DSA run of the right MCA 
the next day showing a vessel wall irregularity. (C) DSA run after 2 years 
of follow- up showing formation of a dissecting pseudoaneurysm located 
in the treated vessel segment. (D) Black blood contrast enhanced axial 
T1 reconstructed MRI slice showing vessel wall enhancement on the 
right MCA bifurcation.
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affected vessel branch is eloquent, meaning that a potentially 
new or additional disabling clinical deficit is to be expected, EVT 
should be attempted. In the case of an inaccessible occlusion and/
or in the absence of contraindications, intra- arterial thrombol-
ysis using urokinase or recombinant tissue plasminogen activator 
can also be considered as a bail- out option43 (figure 3).
PREVENTION
The use of balloon- guide catheters (BGCs) and distal aspiration 
catheters has been reported to result in less frequent emboli-
zation,33 although many factors can influence the outcome. A 
meta- analysis and review that included more than 2000 patients 
was recently published by Brinjikji et al (2018)30. They found 
that using a BGC during EVT for stroke treatment led to signifi-
cantly higher rates of good neurological outcome and nearly half 
the mortality rate of non- BGC- treated patients. The TICI 3 reca-
nalization rates were 20% higher than in the non- BGC- treated 
patients and a reduction in procedure time of over 20 min was 
also noted.
Device-related adverse events
Inadvertent detachment of the SR is rare. An overall incidence 
of <1% to 4% of this device- related complication during the 
treatment of anterior and posterior circulation stroke has been 
reported.44 45 Inadvertent detachment has been shown to be 
associated with a higher number of retrieval attempts and to 
result in a significant increase of sICH and poor outcome. SRs 
currently in use are not detachable, and the stent part of the 
device is firmly molded onto the delivery/push wire. Attempts to 
remove detached SRs employing a wide range of techniques have 
been reported. These included the use of microsnare devices, 
manual aspiration, or use of a second mechanical thrombectomy 
device.38 45 46 The risk–benefit ratio of the different recapture 
techniques has to be considered since retrieval of the SR may 
lead to further complications, such as vessel wall injury, causing 
vessel perforation, dissection, or severe vasospasm. Another 
approach is to leave the stent in place and use conservative 
management with long- term antiplatelet therapy.38 The adminis-
tration of antiplatelet medications in the acute phase of ischemic 
stroke may be associated with an increased risk of sICH.47
Long-term complications after EVT
It is more than 5 years since RCTs established EVT as the stan-
dard treatment procedure for LVO, but few studies of long- term 
complications and sequelae after EVT have been published. SRs 
expose the endothelium to mechanical forces, which may damage 
the wall of the target vessels, as demonstrated by in vivo animal 
studies.48 49 In a case series of 116 patients, follow- up DSA was 
performed after EVT to investigate morphological changes of 
the target vessel. Secondary vessel occlusion was found in one 
(0.9%) and de novo stenosis in four patients (3.4%); however, 
all lesions were clinically asymptomatic.50 The most likely mech-
anism of stenosis formation after EVT is induced by endothelial 
trauma or microdissection. Potentially, iatrogenic microdissec-
tion of the vessel wall can lead to the formation of a pseudoan-
eurysm, which is a rare but recognized late complication after 
EVT, as we show in figure 4. In two other case series, follow- up 
MR angiography was performed after 3 months in 27 patients 
and after 12 months in 39 patients. Vessel abnormalities were 
observed in 2 (8.3%) in the first study and 10 patients (13%) 
in the second.51 52 Antiplatelet therapy has been shown to have 
an inhibitory effect on intimal hyperplasia and on restenosis53 54 
and is usually administered after stroke treatment for secondary 
Table 2 Summary of stroke thrombectomy complications (% in randomized controlled trials), their prevention, and management suggestions
Complication % in RCTs Prevention Management
Extracranial or access site Groin hematoma 2–10%3 4 6 8 Vascular access under ultrasound guidance  ► Watchful observation
 ► Thrombin injection
 ► Implantation of covered stents
Vasospasm 3,9–23%5 6 8 If anticipated or seen early, injection of a 
calcium blocker such as nimodipine (0.5–
1 mg/500 mL infusion) through the flushing 
line of the guiding catheter might help
 ► Selective injection of a calcium blocker such 
as nimodipine as a bolus
 ► Selective injection of a calcium blocker such 
as nimodipine (0.5–1 mg/500 mL infusion) 
through the flushing line of the guiding 
catheter
 ► BEWARE: can cause hypotension and steal 
phenomena!
Dissection 0,6–3,9%2 3 6 Evaluation of access vessel anatomy prior to 
intervention to plan approach
 ► Watchful observation
 ► In cases of increasing stenosis stent 
placement
Hemorrhagic Vessel perforation 0,6–4,9%2–6 J- shaped microwire, passing thrombus with 
microcatheter only, unsheathing rather than 
pushing a stent retriever
 ► Do not pull back the perforating device
 ► Reduce blood pressure temporarily
 ► Deploy a coil temporarily
 ► Prepare a balloon to inflate
 ► Balloon inflation (5–10 min)
 ► LAST: permanent occlusion by detaching coils 
or liquid embolic agent
Ischemic Distal embolization 4–6%40 Flow- arrest devices—for example, balloon- 
guide catheters, distal aspiration catheters
 ► If affected vessel is eloquent consider 
endovascular thrombectomy again
 ► In cases of inaccessibility of distal emboli 
intra- arterial thrombolysis using urokinase or 
rtPA can be considered
De novo stenosis of target 
vessel
(long term)
3,4%51 Antiplatelet therapy as secondary prevention 
after stroke treatment, follow- up imaging to 
monitor long- term complications
 ► Depending on grade of stenosis, clinical 
relevance, and cause, endovascular re- 
treatment might be necessary
rtPA, recombinant tissue plasminogen activator.
by copyright.













6 Pilgram- Pastor SM, et al. J NeuroIntervent Surg 2021;0:1–7. doi:10.1136/neurintsurg-2021-017349
Ischemic stroke
prevention, which might help to explain why significant or 
symptomatic stenosis is rarely seen after EVT.
CONCLUSION
RCTs and case series investigating EVT are primarily focused 
on recanalization rates and clinical outcome. Although the 
evidence- based use of EVT is recommended in multiple interna-
tional guidelines, few recommendations for the management of 
complications are available (for summary see table 2). Interest-
ingly an extended time window up to 24 hours for EVT in the 
DAWN or DEFUSE trial for carefully selected patients did not 
increase complication rates substantially.55 56 However, a system-
atic classification of complications of endovascular stroke treat-
ment is lacking. Different classification systems, nomenclatures, 
and definitions of complications exist, making it hard, or even 
impossible, to compare complications and their management. 
There is therefore a need for classification and reporting stan-
dards for clinical practice and trial conduct. This would pave the 
way for the development of guidelines and treatment standards 
for the management of complications of endovascular stroke 
treatment.
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